What is the price target for SKYE stock?
14 analysts have analysed SKYE and the average price target is 8.89 USD. This implies a price increase of 1134.53% is expected in the next year compared to the current price of 0.72.
NASDAQ:SKYE • US83086J2006
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for SKYE BIOSCIENCE INC (SKYE).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-09-30 | HC Wainwright & Co. | Initiate | Buy |
| 2025-08-15 | Evercore ISI Group | Initiate | Outperform |
| 2025-06-24 | JMP Securities | Reiterate | Market Outperform -> Market Outperform |
| 2025-03-21 | Citizens Capital Markets | Reiterate | Market Outperform -> Market Outperform |
| 2025-03-21 | Craig-Hallum | Maintains | Buy -> Buy |
| 2025-02-28 | William Blair | Initiate | Outperform |
| 2024-09-30 | ScotiaBank | Initiate | Sector Outperform |
| 2024-09-20 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-09-20 | Piper Sandler | Reiterate | Overweight -> Overweight |
| 2024-09-10 | JMP Securities | Initiate | Market Outperform |
| 2024-09-09 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-09-06 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-08-27 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-07-09 | Craig-Hallum | Initiate | Buy |
| 2024-07-01 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-06-18 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-06-17 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2024-05-23 | Cantor Fitzgerald | Initiate | Overweight |
| 2024-04-12 | Oppenheimer | Initiate | Outperform |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A 411.29% | N/A 83.87% | N/A 47.88% | ||||||||||||
| EBITDA YoY % growth | -4.31M | -4.46M -3.48% | -3.85M 13.68% | -4.69M -21.82% | -6.63M -41.36% | -6.29M 5.13% | -7.82M -24.32% | -11.99M -53.32% | -34.763M -189.93% | -36.129M -3.93% | -57.44M -58.99% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -4.32M | -4.47M -3.47% | -3.86M 13.65% | -4.69M -21.50% | -6.63M -41.36% | -6.29M 5.13% | -7.85M -24.80% | -12.11M -54.27% | -34.887M -188.08% | -36.427M -4.42% | -58.164M -59.67% | N/A 15.83% | N/A -34.78% | N/A -42.62% | N/A -49.25% | N/A -22.50% | N/A 39.80% | N/A 71.81% | N/A 304.28% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -0.72 87.00% | -3.65 -406.94% | N/A 71.65% | N/A -16.67% | N/A -21.33% | N/A -21.52% | N/A -10.79% | N/A 44.82% | N/A 73.12% | N/A 269.76% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.32 -14.99% | -0.24 91.08% | -0.24 24.99% | -0.25 30.49% | -0.29 11.06% | -0.28 -18.32% | -0.28 -18.13% | -0.30 -19.23% |
| Revenue Q2Q % growth | ||||||||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -12.719M -8.16% | -12.689M 30.45% | -12.781M 3.65% | -13.178M 11.53% | -19.21M -51.03% | -19.89M -56.75% | -20.4M -59.62% | -21.08M -59.96% |
All data in USD
14 analysts have analysed SKYE and the average price target is 8.89 USD. This implies a price increase of 1134.53% is expected in the next year compared to the current price of 0.72.
SKYE BIOSCIENCE INC (SKYE) will report earnings on 2026-05-06.
The consensus EPS estimate for the next earnings of SKYE BIOSCIENCE INC (SKYE) is -0.32 USD and the consensus revenue estimate is 0 USD.
The number of analysts covering SKYE BIOSCIENCE INC (SKYE) is 14.